-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 UArwJ0/3NyTL+aUIdtblC5ogmIsbayjFbb2qezCSqnqGsSRahOcHzczIEtu/HrpP
 xizcjShuDd9LXN+iogucuA==

<SEC-DOCUMENT>0001275287-06-003482.txt : 20060707
<SEC-HEADER>0001275287-06-003482.hdr.sgml : 20060707
<ACCEPTANCE-DATETIME>20060707160049
ACCESSION NUMBER:		0001275287-06-003482
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20060630
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20060707
DATE AS OF CHANGE:		20060707

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANIKA THERAPEUTICS INC
		CENTRAL INDEX KEY:			0000898437
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				043145961
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14027
		FILM NUMBER:		06951378

	BUSINESS ADDRESS:	
		STREET 1:		236 WEST CUMMINGS PARK
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
		BUSINESS PHONE:		6179326616

	MAIL ADDRESS:	
		STREET 1:		236 WEST CUMMINGS PARK
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA RESEARCH INC
		DATE OF NAME CHANGE:	19930309
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>at6297.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<html>

<head>
<title></title>
</head>

<body bgcolor="white">




<hr size="4" width="100%" noshade color=black>


<p  align="center"><font size="5" face="Times New Roman"><b>UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION<br> </b></font>
<font size="3"><b>WASHINGTON, D.C. 20549</b></font></p>
<p  align="center">
<font size="5" face="Times New Roman"><b>FORM 8-K</b></font></p>
<p  align="center">
<font size="3" face="Times New Roman"><b>CURRENT REPORT<br> PURSUANT TO SECTION 13 OR 15(d) OF THE<br> SECURITIES EXCHANGE ACT OF 1934</b></font></p>
<p  align="center">
<font size="2" face="Times New Roman"><b>Date of Report (Date of earliest event reported): June 30, 2006</b></font></p>
<table align="center"  border="0" style="border-collapse:collapse" cellspacing="0"  cellpadding="0"  width="100%">

 <tr>
  <td  colspan="5"  valign="top">
  <p align="center" style="margin-left:1em; text-indent:-1em">
<font size="6" face="Times New Roman"><b>Anika   Therapeutics,&nbsp;Inc.</b></font></p>  </td>
 </tr>
 <tr>
  <td  colspan="5"  valign="top">
  <p align="center" style="margin-left:1em; text-indent:-1em">
<font size="2" face="Times New Roman"><i>(Exact Name of Registrant as Specified in Its   Charter)</i></font></p>  </td>
 </tr>
 <tr>
  <td width="32%" valign="top">
  <p style="margin-left:1em; text-indent:-1em">
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td width="2%" valign="top">
  <p style="margin-left:1em; text-indent:-1em">
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td width="32%" valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td width="2%" valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td width="32%" valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
 </tr>
 <tr>
  <td  valign="top">
  <p align="center" style="margin-left:1em; text-indent:-1em">
<font size="2" face="Times New Roman"><b>Massachusetts</b></font></p>  </td>
  <td  valign="top">
  <p style="margin-left:1em; text-indent:-1em"><font size=1 face="Times New Roman">&nbsp;</font></p> </td>
  <td  valign="top">
  <p  align="center">
<font size="2" face="Times New Roman"><b>000-21326</b></font></p>  </td>
  <td  valign="top">
  <p  align="center"><font size=1 face="Times New Roman">&nbsp;</font></p> </td>
  <td  valign="top">
  <p  align="center">
<font size="2" face="Times New Roman"><b>04-3145961</b></font></p>  </td>
 </tr>
 <tr>
  <td  valign="top">
  <p align="center"><font size="2" face="Times New Roman"><i>(State or Other Jurisdiction<br>   of Incorporation)</i></font></p>  </td>
  <td  valign="top">
  <p style="margin-left:1em; text-indent:-1em"><font size=1 face="Times New Roman">&nbsp;</font></p> </td>
  <td  valign="top">
  <p  align="center">
<font size="2" face="Times New Roman"><i>(Commission <br>File Number)</i></font></p>  </td>
  <td  valign="top">
  <p  align="center"><font size=1 face="Times New Roman">&nbsp;</font></p> </td>
  <td  valign="top">
  <p  align="center">
<font size="2" face="Times New Roman"><i>(I.R.S. Employer <br>   Identification No.)</i></font></p>  </td>
 </tr>
 <tr>
  <td  valign="top">
  <p style="margin-left:1em; text-indent:-1em">
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td  valign="top">
  <p style="margin-left:1em; text-indent:-1em">
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td  valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td  valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td  valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
 </tr>
 <tr>
  <td  colspan="3"  valign="top">
  <p align="center" style="margin-left:1em; text-indent:-1em">
<font size="2" face="Times New Roman"><b>160   New Boston Street, Woburn, Massachusetts</b></font></p>  </td>
  <td  valign="top">
  <p style="margin-left:1em; text-indent:-1em">
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td  valign="top">
  <p  align="center">
<font size="2" face="Times New Roman"><b>01801</b></font></p>  </td>
 </tr>
 <tr>
  <td  colspan="3"  valign="top">
  <p align="center" style="margin-left:1em; text-indent:-1em">
<font size="2" face="Times New Roman"><i>(Address of Principal Executive Offices)</i></font></p>  </td>
  <td  valign="top">
  <p style="margin-left:1em; text-indent:-1em">
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td  valign="top">
  <p  align="center">
<font size="2" face="Times New Roman"><i>(Zip Code)</i></font></p>  </td>
 </tr>
 <tr>
  <td  valign="top">
  <p style="margin-left:1em; text-indent:-1em">
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td  valign="top">
  <p style="margin-left:1em; text-indent:-1em">
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td  valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td  valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td  valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
 </tr>
 <tr>
  <td  colspan="5"  valign="top">
  <p align="center" style="margin-left:1em; text-indent:-1em"><font size="2" face="Times New Roman"><b>Registrant&#146;s   Telephone Number, Including Area Code:</b><b> (781)&nbsp;932-6616</b></font></p>  </td>
 </tr>
 <tr>
  <td  valign="top">
  <p style="margin-left:1em; text-indent:-1em">
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td  valign="top">
  <p style="margin-left:1em; text-indent:-1em">
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td  valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td  valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td  valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
 </tr>
 <tr>
  <td  colspan="5"  valign="top">
  <p align="center" style="margin-left:1em; text-indent:-1em">
<font size="2" face="Times New Roman"><b>No   Change Since Last Report</b></font></p>  </td>
 </tr>
 <tr>
  <td  colspan="5"  valign="top">
  <p align="center" style="margin-left:1em; text-indent:-1em">
<font size="2" face="Times New Roman"><i>(Former name or former address, if changed since last   report)</i></font></p>  </td>
 </tr>
</table>

<p>
<font size="2" face="Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</font></p>
<table align="center"  border="0" style="border-collapse:collapse" cellspacing="0"  cellpadding="0"  width="100%">

 <tr>
  <td width="5%" valign="top">
  <p>
<font size="2" face="Wingdings">o</font></p>  </td>
  <td width="95%" valign="top">
  <p>
<font size="2" face="Times New Roman">Written communications pursuant to Rule 425 under   the Securities Act (17 CFR 230.425)</font></p>  </td>
 </tr>
 <tr>
  <td  valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td  valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
 </tr>
 <tr>
  <td  valign="top">
  <p>
<font size="2" face="Wingdings">o</font></p>  </td>
  <td  valign="top">
  <p>
<font size="2" face="Times New Roman">Soliciting material pursuant to Rule 14a-12 under   the Exchange Act (17 CFR 240.14a-12)</font></p>  </td>
 </tr>
 <tr>
  <td  valign="top">
  <p><font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td  valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
 </tr>
 <tr>
  <td  valign="top">
  <p>
<font size="2" face="Wingdings">o</font></p>  </td>
  <td  valign="top">
  <p>
<font size="2" face="Times New Roman">Pre-commencement communications pursuant to Rule   14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></p>  </td>
 </tr>
 <tr>
  <td  valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td  valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
 </tr>
 <tr>
  <td  valign="top">
  <p>
<font size="2" face="Wingdings">o</font></p>  </td>
  <td  valign="top">
  <p>
<font size="2" face="Times New Roman">Pre-commencement communications pursuant to Rule   13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></p>  </td>
 </tr>
 <tr>
  <td  valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td  valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
 </tr>
 <tr>
  <td  colspan="2" valign="top">
  <hr size="4" width="100%" noshade color=black>

  </td>
 </tr>
</table>

<br>


<div style="page-break-before:always"></div>
<PAGE>
<br>

<p  align="center">
<font size="2" face="Times New Roman"><b>Section 1 &#150; Registrant&#146;s Business and Operations</b></font></p>
<p>
<font size="2" face="Times New Roman"><b>Item 1.01 Entry into a Material Definitive Agreement </b></font></p>
<p>
<font size="2" face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On June 30, 2006, Anika Therapeutics, Inc. (the &#147;Company&#148;) entered into a License and Development Agreement (the &#147;License Agreement&#148;) with Galderma Pharma S.A., a joint venture between Nestl&#233; and L&#146;Or&#233;al (&#147;Galderma&#148;), and a Supply Agreement (together with the License Agreement, the &#147;Agreements&#148;) with Galderma and Galderma S.A., an affiliate of Galderma, for the exclusive worldwide development and commercialization of hyaluronic acid based cosmetic tissue augmentation (&#147;CTA&#148;) products.&#160; Pursuant to the Agreements, Anika will be responsible for the development and manufacturing of the CTA products, and Galderma will be responsible for the commercialization, including distribution and marketing, of the CTA products worldwide.</font></p>

<p><font size="2" face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the terms of the Agreements, the Company will receive a non-refundable, upfront payment of $1 million.&#160; The Agreements also set forth milestone events related to final regulatory approvals of the CTA products in the United States and Europe, respectively, that, if achieved, would entitle the Company to aggregate milestone payments of up to $5 million for the initial CTA product and up to an additional $1.5 million for each additional CTA product that the parties agree to develop and market.&#160; In addition, the Agreements provide the Company with transfer payments for supplying Galderma with the CTA products and royalties based on sales of the Company&#146;s CTA products by Galderma to its customers.&#160; The Agreements also provide for a number of additional milestone payments of up to $14.5 million if CTA product net sales exceed certain net sales targets.&#160; Under the terms of the
Agreements, Galderma will support the development of the Company&#146;s CTA products, including reimbursement for certain development costs for the enhancement of the initial CTA product, line extensions and clinical trial support, and the Company will make appropriate regulatory filings with the U.S. Food and Drug Administration and regulators in the European Union to enhance features of its initial CTA product.</font></p>
<p>
<font size="2" face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Agreements have an initial term of ten years, unless earlier terminated pursuant to any one of several early termination rights of each party.&#160; In certain circumstances, an early termination of the Agreements will require the Company to refund to Galderma certain product development milestone payments and reimbursements of development costs.&#160; Following the initial term, the Agreements will automatically renew for an additional three year period if a certain net sales target has been exceeded, unless terminated by Galderma prior to the expiration of the initial term.</font></p>
<p>
<font size="2" face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The foregoing description of the Agreements does not purport to be complete and is qualified in its entirety by reference to the text of the Agreements, which will be filed with the Company&#146;s Quarterly Report on Form 10-Q for the period ending June&nbsp;30, 2006, unless earlier terminated or filed.&#160; </font></p>

<p><font size="2" face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company issued a press release concerning the Agreements, which is attached hereto as Exhibit&nbsp;99.1.</font></p>
<p  align="center">
<font size="2" face="Times New Roman"><b>Section&nbsp;9 &#150; Financial Statements and Exhibits</b></font></p>
<p>
<font size="2" face="Times New Roman"><b>Item 9.01&nbsp; Financial Statements and Exhibits.</b></font></p>
<p>
<font size="2" face="Times New Roman">(d) Exhibits</font></p>
<table align="center"  border="0" style="border-collapse:collapse" cellspacing="0"  cellpadding="0"  width="100%">

 <tr>
  <td width="10%" valign="top">
  <p>
<font size="1" face="Times New Roman"><b>Exhibit No.</b></font></p>  </td>
  <td width="5%" valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td width="85%" valign="top">
  <p>
<font size="1" face="Times New Roman"><b>Description</b></font></p>  </td>
 </tr>
 <tr>
  <td  valign="top">
  <hr size="1" width="100%" noshade color=black>

  </td>
  <td  valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td  valign="top">
  <hr size="1" width="100%" noshade color=black>

  </td>
 </tr>
 <tr>
  <td  valign="top">
  <p>
<font size="2" face="Times New Roman">99.1</font></p>  </td>
  <td  valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td  valign="top">
  <p>
<font size="2" face="Times New Roman">Press Release issued by   Anika Therapeutics, Inc. on July 5, 2006</font></p>  </td>
 </tr>
</table>

<br>

<hr size="1" width="100%" noshade color=black>
<div style="page-break-before:always"></div>
<PAGE>
<br>

<p  align="center">
<font size="2" face="Times New Roman"><b>SIGNATURES</b></font></p>
<p>
<font size="2" face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.</font></p>

<table align="center"  border="0" style="border-collapse:collapse" cellspacing="0"  cellpadding="0"  width="100%">

 <tr>
  <td  valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td  colspan="2" valign="top">
  <p>
<font size="2" face="Times New Roman">ANIKA THERAPEUTICS, INC.</font></p>  </td>
 </tr>
 <tr>
  <td width="60%" valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td width="4%" valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td width="36%" valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
 </tr>
 <tr>
  <td  valign="top">
  <p>
<font size="2" face="Times New Roman">July 7, 2006</font></p>  </td>
  <td  valign="top">
  <p>
<font size="2" face="Times New Roman">By:</font></p>  </td>
  <td  valign="top">
  <p>
<font size="2" face="Times New Roman">/s/ Kevin W. Quinlan</font></p>  </td>
 </tr>
 <tr>
  <td  valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td  valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td  valign="top">
  <hr size="1" width="100%" noshade color=black>

  </td>
 </tr>
 <tr>
  <td  valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td  valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td  valign="top">
  <p>
<font size="2" face="Times New Roman">Kevin W. Quinlan</font></p>  </td>
 </tr>
 <tr>
  <td  valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td  valign="top">
  <p>
<font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td  valign="top">
  <p>
<font size="2" face="Times New Roman"><i>Chief   Financial Officer</i></font></p>  </td>
 </tr>
</table>

<br>

<hr size="1" width="100%" noshade color=black>
<div style="page-break-before:always"></div>
<PAGE>
<br>


<p  align="center"><font size="2" face="Times New Roman"><b>Exhibit Index</b></font></p>
<table align="center"  border="0" style="border-collapse:collapse" cellspacing="0"  cellpadding="0"  width="100%">

 <tr>
  <td width="10%" valign="top">
  <p><font size="1" face="Times New Roman"><b>Exhibit No.</b></font></p>  </td>
  <td width="5%" valign="top">
  <p><font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td width="85%" valign="top">
  <p><font size="1" face="Times New Roman"><b>Description</b></font></p>  </td>
 </tr>
 <tr>
  <td  valign="top">
  <hr size="1" width="100%" noshade color=black>

  </td>
  <td  valign="top">
  <p><font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td  valign="top">
  <hr size="1" width="100%" noshade color=black>

  </td>
 </tr>
 <tr>
  <td  valign="top">
  <p><font size="2" face="Times New Roman">99.1</font></p>  </td>
  <td  valign="top">
  <p><font size="1" face="Times New Roman">&nbsp;</font></p>  </td>
  <td  valign="top">
  <p><font size="2" face="Times New Roman">Press Release issued by   Anika Therapeutics, Inc. on July 5, 2006</font></p>  </td>
 </tr>
</table>

<br>

<hr size="1" width="100%" noshade color=black>

</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>at6297ex991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>

<head>
<title></title>
</head>

<body bgcolor="white">


<p  align="right"><font size="2" face="Times New Roman"><b>Exhibit 99.1</b></font></p>

<p  align="center"><font size="2" face="Times New Roman"><b>Anika Therapeutics Announces Worldwide Development and Commercialization Agreement with Galderma Pharma</b></font></p>
<p>
<font size="2" face="Times New Roman">WOBURN, Mass., July 5 /PRNewswire-FirstCall/ -- Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it has signed an exclusive worldwide development and commercialization agreement with Galderma Pharma S.A., a joint venture between Nestle and L&#146;Oreal, for cosmetic tissue augmentation (&#147;CTA&#148;) therapies. CTA therapies are used in patients for the correction of facial wrinkles, scar remediation, and lip augmentation.</font></p>
<p>
<font size="2" face="Times New Roman">Anika will receive an upfront payment of $1 million with additional milestone payments to be made upon receipt of final regulatory approvals and upon achievement of sales thresholds and development targets. The agreement also provides Anika with royalties and transfer payments for the supply of CTA products.</font></p>
<p>
<font size="2" face="Times New Roman">&#147;We are delighted to reach agreement with Galderma and excited about the potential growth in this expanding aesthetic marketplace,&#148; said Anika President and Chief Executive Officer Charles H. Sherwood, Ph.D. &#147;Galderma&#146;s demonstrated marketing and distribution expertise, and outstanding reputation for success has established them as one of the premier dermatological companies. We look forward to working together to meet the needs of patients.&#148;</font></p>
<p>
<font size="2" face="Times New Roman">&#147;We believe Anika&#146;s know-how has tremendous potential to produce innovative solutions to currently unmet needs in Aesthetic Dermatology. Galderma&#146;s commitment to bring products to market worldwide reflects our long term commitment to continuously strive to meet the needs of dermatology patients,&#148; says Humberto C. Antunes, Chief Executive Officer of Galderma.</font></p>
<p>
<font size="2" face="Times New Roman">Under this multiyear agreement, which is subject to earlier termination pursuant to certain events, Galderma will also reimburse certain development costs for enhancement of the initial product, line extensions, and clinical trial support. Anika anticipates filing amendments to its existing regulatory applications with the FDA and European Union regulators to enhance features of its CTA product. Commercialization of the enhanced version of the CTA product is estimated to commence mid-2007.</font></p>

<p><font size="2" face="Times New Roman">About Anika Therapeutics, Inc.</font></p>
<p>
<font size="2" face="Times New Roman">Headquartered in Woburn, Mass., Anika
Therapeutics, Inc. (http://www.anikatherapeutics.com) develops, manufactures and
commercializes therapeutic products for tissue protection and healing. These
products are based on hyaluronic acid (HA), a naturally occurring, biocompatible
polymer found throughout the body. Anika products include OrthoVisc&#174;, a
treatment for osteoarthritis of the knee available internationally and marketed
in the U.S. by DePuy Mitek, and Hyvisc&#174;, a treatment for equine osteoarthritis
marketed in the U.S. by Boehringer Ingelheim Vetmedica, Inc. Anika manufactures
Amvisc<sup>(TM)</sup> and Amvisc Plus<sup>(TM)</sup>, HA viscoelastic products for ophthalmic surgery.
It also produces STAARVISC<sup>(TM)</sup>-II, which is distributed by STAAR Surgical
company and Shellgel<sup>(TM)</sup> for Cytosol Ophthalmics, Inc.</font></p>

<hr size="1" width="100%" noshade color=black>
<div style="page-break-before:always"></div>
<PAGE>
<br>

<p>
<font size="2" face="Times New Roman">About Galderma</font></p>
<p>
<font size="2" face="Times New Roman">Galderma (http://www.galderma.com), the number one pharmaceutical company in dermatology (IMS Health, IMS Dataview -- D class -- MAT Q4 2005, 33 countries), focuses exclusively on meeting the needs of dermatology patients and physicians by providing innovative therapeutic solutions for the diagnosis, prevention and treatment of dermatological conditions. Its expertise spans a broad spectrum of skin, hair and nail diseases, with a strong position on acne, rosacea, onychomycosis, psoriasis, hyperpigmentation disorders and non-melanoma skin cancers and photodamage.</font></p>
<p>
<font size="2" face="Times New Roman">Prescription products include DIFFERIN&#174;
for the treatment of acne, METROGEL&#174; and ROZEX&#174; for the treatment of
rosacea, LOCERYL&#174; Nail Lacquer for the treatment of onychomychosis and
TRI-LUMA&#174; for the treatment of melasma as well as therapeutic skin care
products with CETAPHIL&#174;.</font></p>
<p>
<font size="2" face="Times New Roman">Recently launched products include the
innovative drug delivery formulations CLOBEX&#174; Shampoo for scalp psoriasis and
CLOBEX&#174; Spray for psoriasis, METVIX&#174; (Australia and 11 countries in Europe)
for actinic keratosis, basal cell carcinoma and Bowen&#146;s disease and
METROGEL&#174; 1% for the treatment of rosacea.</font></p>
<p>
<font size="2" face="Times New Roman">Created in 1981, Galderma Pharma S.A. is a 50/50 joint venture between Nestle and L&#146;Oreal based in Lausanne, Switzerland. The company deploys a worldwide network of 33 fully owned subsidiaries, employs 2,370 people with products marketed in more than 65 countries.</font></p>

<p><font size="2" face="Times New Roman">The statements made in this press release which are not statements of historical fact are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, without limitation, statements that may be identified by words such as &#147;expectations,&#148; &#147;remains,&#148; &#147;focus,&#148; &#147;expected,&#148; &#147;prospective,&#148; &#147;expanding,&#148; &#147;building,&#148; &#147;continue,&#148; &#147;progress,&#148; &#147;efforts,&#148; &#147;hope,&#148; &#147;believe,&#148; &#147;objectives,&#148; &#147;opportunities,&#148; &#147;will,&#148; &#147;seek,&#148; and other expressions which are predictions of or indicate future events and trends and which do not constitute historical matters identify forward-looking statements. The statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and
other factors. The Company&#146;s actual results could differ materially from any anticipated future results, performance or achievements described in the forward-looking statements as a result of a number of factors including: its ability to successfully receive FDA or foreign regulatory approvals for its CTA products; that even if received, such approvals will not be obtained in a timely manner or without the need for additional clinical trials; and the results of its research and product development efforts and their relative success and timing of regulatory approvals, commercialization of the Company&#146;s products; the risk that the Company&#146;s new arrangements with Galderma will not result in any meaningful sales or will be terminated at an earlier date in accordance with its terms, or that Galderma will fail to perform as it has committed to under the agreement, or that any of the milestones in this agreement will not be achieved. Even if the Company is successful with its CTA product or
its other products, there can be no assurance that it will be successful with other potential products. Certain other factors that might cause the Company&#146;s actual results to differ materially from those in the forward-looking statements include those set forth under the headings &#147;Business,&#148; &#147;Risk Factors,&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; in each of the Company&#146;s Annual Report on Form 10-K for the year ended December 31, 2005 and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2006 and current reports on Form 8-K, as well as those described in the Company&#146;s other press releases and SEC filings.</font></p>


<p><font size="2" face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contact:<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anika Therapeutics, Inc.<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Charles Sherwood, Ph.D., CEO<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Kevin Quinlan, CFO<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(781) 932-6616</font></p>
<p><font size="2" face="Times New Roman">SOURCE&#160; Anika Therapeutics, Inc.<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-0-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;07/05/2006<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/CONTACT: Charles Sherwood, Ph.D., CEO, or Kevin Quinlan, CFO, both of<br> Anika Therapeutics, Inc., +1-781-932-6616 /<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/Web site:&#160; http://www.anikatherapeutics.com<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;http://www.galderma.com /<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ANIK)</font></p>

<hr size="1" width="100%" noshade color=black>


</body>

</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
